Results 141 to 150 of about 160,542 (279)

Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background Patients with early‐stage cutaneous melanoma (CM) have low individual risk but account for most distant recurrences. The utility of gene expression profiling (GEP) in CM risk stratification and clinical management remains unclear. Methods From 2015 to 2022, CM patients at a single center were universally referred for DecisionDx 31 ...
Daniel B. Gehle, Philip W. Morgan, Emme M. Fitts, Nathaniel L. Hauser, Chelsea R. Olson, Andrew M. Fleming, Julia Pedo Freitas, Feng Liu‐Smith, Simonne S. Nouer, Andrew J. Murphy, Martin D. Fleming   +10 more
wiley   +1 more source

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

Cost Effectiveness and Resource Allocation
Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu   +6 more
doaj   +1 more source

Management of Satellite Lesions in Hepatocellular Carcinoma: An Updated Review

Journal of Surgical Oncology, EarlyView.
ABSTRACT Satellite lesions, defined as microscopic or small macroscopic tumor nodules within 2 cm of a primary hepatocellular carcinoma (HCC), represent early intrahepatic dissemination and are strongly associated with aggressive tumor biology.
Andy Tran, Mohammed O. Suraju, Ihuoma Tasie, Abdelrahman K. Abdalla, Hassan Aziz   +4 more
wiley   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Introduction Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Long‐Term Clinical Response After Low‐Dose and Short‐Duration Cemiplimab Therapy in a Patient With Xeroderma Pigmentosum in Nepal

JEADV Clinical Practice, EarlyView.
ABSTRACT Xeroderma pigmentosum (XP), an autosomal recessive condition affecting DNA repair, is associated with a high risk of multiple and aggressive cutaneous squamous cell carcinomas (CSCCs). Because of numerous and/or locally advanced tumors, surgery may be difficult.
Sudip Parajuli, Arnab Panta, Sabina Bhandari, Anne Grange, Florent Grange, Upama Paudel   +5 more
wiley   +1 more source

Efectividad de la inmunoterapia con pembrolizumab versus inmunoterapia con pembrolizumab combinada con quimiorradiación en el cáncer de cérvix. Revisión sistemática

El cáncer de cérvix es una neoplasia maligna que se origina en las células del cuello del útero, ocasionado por una infección de transmisión sexual del virus del papiloma humano, es una patología de alta incidencia entre las mujeres alrededor del mundo ...
Rivera Chicaiza, Erika Johanna
core  

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres, Jessi M. Larrinaga, Katherine Bodiford, Olayemi Sokumbi, Leila Tolaymat   +4 more
wiley   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoadjuvant therapy have a high risk of recurrence even with neoadjuvant and adjuvant treatment with pembrolizumab.
DeMichele, Angela, Rugo, Hope S, Carey, Lisa A, Takano, Toshimi, Perou, Charles, Tolaney, Sara M, Mocci, Simonetta, Partridge, Ann H, Parsons, Heather Anne, Lynce, Filipa, Rocque, Gabrielle Betty, Sun, Shawn W, Santa-Maria, Cesar Augusto, Yao, Wenliang   +13 more
core   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source